Prevalence of Functional Bowel Disorders and Related Health Care Seeking: A Population-Based Study

Icks, A.; Haastert, B; Enck, Paul; Rathmann, W; G, Giani

doi:10.1055/s-2002-22324

Cited by 51 publications

(43 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in line with the prevalence of IBS of 11.5% reported by Hungin and colleagues, based on a community-based survey of over 40,000 subjects living in several European countries [3]. In Germany, the prevalence of IBS is up to 12.5% [4]. The majority of sufferers from abdominal cramping and pain or IBS use self-medication with over-the-counter (OTC) drugs to relieve their symptoms [4,5].…”

Section: Introductionsupporting

confidence: 83%

See 1 more Smart Citation

Symptoms and Their Interpretation in Patients Self-Treating Abdominal Cramping and Pain with a Spasmolytic (Butylscopolamine Bromide)—A Pharmacy-Based Survey

Müller-Lissner¹,

Schäfer²,

Kondla³

2011

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 83%

“…In Germany, the prevalence of IBS is up to 12.5% [4]. The majority of sufferers from abdominal cramping and pain or IBS use self-medication with over-the-counter (OTC) drugs to relieve their symptoms [4,5].…”

Section: Introductionmentioning

confidence: 99%

Symptoms and Their Interpretation in Patients Self-Treating Abdominal Cramping and Pain with a Spasmolytic (Butylscopolamine Bromide)—A Pharmacy-Based Survey

Müller-Lissner¹,

Schäfer²,

Kondla³

2011

View full text Add to dashboard Cite

show abstract

“…11,16 This trend is also seen in self-medication with over-the-counter (OTC) drugs, although the majority of patients with IBS receive prescription medications. 3,[17][18] While many drugs have been used in the treatment of IBS in the United States, only 2 drugs have been approved by the U.S. Food and Drug Administration specifically for this indication. 12 Tegaserod (Zelnorm), a partial serotonin-4 receptor agonist, was voluntarily withdrawn from the U.S. market in March 2007 because of the risk of cardiovascular ischemic events.…”

Section: Note: This Article Is the Subject Of An Editorial That Appeamentioning

confidence: 99%

Self-Reported Use of Pharmaceuticals Among Patients With Irritable Bowel Syndrome in Primary Care

Faresjö¹,

Grodzinsky²,

Johansson³

et al. 2008

JMCP

View full text Add to dashboard Cite

BACKGROUND: Irritable bowel syndrome (IBS) has an estimated 10%-12% prevalence in industrial countries. Studies from the United States have shown that IBS causes notable financial losses for employers. Due to the lack of pathophysiological markers, only a fraction of the pharmacological management of IBS has focused on etiological mechanisms. We hypothesized that there is a high consumption of nonspecific drugs among patients with IBS in their attempts to manage symptoms.OBJECTIVE: To analyze self-reported use of prescription and over-thecounter (OTC) drugs among patients with IBS in primary care compared with controls from the general population.METHODS: A population-based case-control design was used for the study. IBS cases were identified from the electronic medical records of 3 Swedish primary health care centers from January 1, 1997, through December 31, 2001. A questionnaire containing specific questions about prescription and OTC drugs was mailed in 2003 to 5,015 working-age (18-64 years) individuals (IBS cases and controls) in the Linköping IBS Population Study, a study of primary care patients with controls selected from the general population. RESULTS: After 2 reminders, the overall response rate was 63% (3,074 respondents of 4,913 deliverable surveys); 71% responded for the IBS cases (347/486) and 57% (2,509/4,427) responded for the controls. 72.3% of the IBS respondents and 51.9% of the controls were female. Acid-suppressive agents were the most commonly cited drug category for abdominal complaints reported by IBS patients (13.3%) compared with controls (1.6%) (unadjusted odds ratio [OR] = 9.20, 95% confidence interval [CI] = 5.94-14.25). Antidepressants were the most commonly cited drug category for nonabdominal complaints, reported by 13.3% of IBS patients versus 4.5% of controls (OR = 3.27, 95% CI = 2.27-4.70). An unadjusted univariate correlation analysis revealed that prescription acid-suppressive drugs, fiber and bulking laxatives, and antiflatulents and antidiarrhea drugs, as well as motility-regulating and antispasmodics drugs, were significantly more common among IBS cases compared with controls. In addition to the higher use of antidepressants, there were 3 other drug classes for nongastrointestinal complaints with a higher rate of use among IBS patients compared with controls: sedative hypnotics (OR = 2.49, CI = 1.44-4.29), analgesics (OR = 2.86, CI = 1.88-4.33), and thyroid hormones (OR = 2.43, CI = 1.39-4.26).CONCLUSIONS: There was higher use of antidepressants among patients with IBS compared with controls from the general population. Even though they are not recommended for this patient category, the use of prescription and OTC acid-suppressive drugs is also common among IBS cases in primary care.

show abstract

“…Its prevalence in western countries is estimated between 7 and 15% [2,3,4,5]. In a subset of patients, IBS symptoms may be severe and partly incapacitating, and hence have a considerable impact on the quality of life.…”

Section: Introductionmentioning

confidence: 99%

Tegaserod: Long-Term Treatment for Irritable Bowel Syndrome Patients with Constipation in Primary Care

et al. 2005

View full text Add to dashboard Cite

Background: Tegaserod, a prokinetic 5-HT⁴ receptor agonist, has demonstrated efficacy and tolerability in irritable bowel syndrome (IBS) patients with constipation (IBS-C) in controlled clinical trials. Its use in primary care has not been investigated. Aim: To determine whether tegaserod is effective and well tolerated by primary care IBS-C patients. Methods: Patients received tegaserod 6 mg b.i.d. for 12 weeks and were assessed for response, abdominal pain/discomfort, bloating, stool consistency/frequency and straining at weeks 4 and 12. Previous successful treatment with the withdrawn drug, cisapride, was noted. A 9-month study extension was offered to patients completing 12 weeks of tegaserod treatment. Results: 212 patients entered the 12-week treatment period; 166 completed as planned. Response rates were 64.2% at week 4 and 70.3% at week 12. After 12 weeks, abdominal pain/discomfort and bloating were reduced from baseline (p < 0.0001; mean change –1.02 and –0.91 points, respectively), stool frequency increased (0.78–0.97 stools/day) and stool consistency improved (2.45–3.42; lumpy stools became softer). Tegaserod was well tolerated; the most common adverse events were headache (13.2%) and diarrhea (9.4%). One hundred and twenty patients entered the 9-month extension study, 85 completed and tegaserod continued to be well tolerated. Conclusions: In ambulatory primary care IBS-C patients, tegaserod is an effective and well-tolerated long-term treatment.

show abstract

Prevalence of Functional Bowel Disorders and Related Health Care Seeking: A Population-Based Study

Abstract: A high prevalence of functional bowel disorders was found in this population-based study in Germany. Only about half of the subjects reported health care seeking due to their bowel disorders. Self-medication with over-the-counter agents was frequently performed.

Cited by 51 publications

References 14 publications

Symptoms and Their Interpretation in Patients Self-Treating Abdominal Cramping and Pain with a Spasmolytic (Butylscopolamine Bromide)—A Pharmacy-Based Survey

Symptoms and Their Interpretation in Patients Self-Treating Abdominal Cramping and Pain with a Spasmolytic (Butylscopolamine Bromide)—A Pharmacy-Based Survey

Self-Reported Use of Pharmaceuticals Among Patients With Irritable Bowel Syndrome in Primary Care

Tegaserod: Long-Term Treatment for Irritable Bowel Syndrome Patients with Constipation in Primary Care

Contact Info

Product

Resources

About